Fig. 6: In vivo antitumor performance of ADPAH@AOT-Bro.

a Schematic illustration of in vivo antitumor schedule. b, c Tumor growth curves of (b) primary and (c) distant tumors in 4T1-tumor-bearing mice following various treatments (1064 nm, 5 min, n = 5). ADPAH-Bro@AOT/NIR-II versus ADPAH@AOT/NIR-II in (b): p = 0.373; ADPAH-Bro@AOT/NIR-II versus other three groups in (b): p < 0.001; ADPAH-Bro@AOT/NIR-II versus ADPAH@AOT/NIR-II in (c): p = 0.002. ADPAH-Bro@AOT/NIR-II versus other three groups in (c): p < 0.001. d Immunofluorescent images of active caspase-3 (red) in primary and distant tumor sections following various treatments. e, f Quantification of expression level of active caspase-3 in (e) primary and (f) distant tumors sections from euthanized mice following various treatments (n = 3). ADPAH-Bro@AOT/NIR-II versus ADPAH@AOT/NIR-II in (e): p = 0.005. ADPAH-Bro@AOT/NIR-II versus other three groups in (e): p < 0.001; ADPAH-Bro@AOT/NIR-II versus other groups in (f): p < 0.001. g H&E-stained images of the primary and abscopal tumor sections from euthanized mice following various treatments (n = 3). Data were presented as mean ± SD. Statistical significance in (b), (c), (e) and (f) was calculated via one-way ANOVA followed by Tukey post-hoc test. ns not significant, **p < 0.01, and ***p < 0.001.